Evolution of the thienopyridine class of inhibitors of IκB kinase-β: Part I: Hit-to-lead strategies

Journal of Medicinal Chemistry

Volumn 49, Issue 10, 2006, Pages 2898-2908

  Morwick, Tina ^a   Berry, Angela ^a   Brickwood, Janice ^a   Cardozo, Mario ^a   Catron, Katrina ^a   DeTuri, Molly ^a   Emeigh, Jonathan ^a   Homon, Carol ^a   Hrapchak, Matt ^a   Jacober, Stephen ^a   Jakes, Scott ^a   Kaplita, Paul ^a   Kelly, Terence A ^a   Ksiazek, John ^a   Liuzzi, Michel ^b   Magolda, Ronald ^a   Mao, Can ^a   Marshall, Daniel ^a   McNeil, Daniel ^a   Prokopowicz II, Anthony ^a   Sarko, Christopher ^a   Scouten, Erika ^b   Sledziona, Cynthia ^a   Sun, Sanxing ^a   Watrous, Jane ^a   Wu, Jiang Ping ^a   Cywin, Charles L ^a   more..

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THIOPHENE DERIVATIVE;

ARTICLE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HYDROLYSIS; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

I-KAPPA B KINASE; MODELS, MOLECULAR; OXAZOLES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646751327     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0510979     Document Type: Article

References (53)

1. (a) Davis, A. M.; Keeling, D. J.; Steele, J.; Tomkinson, N. P.; Tinker, A. C. Components of successful lead generation. Curr. Top. Med. Chem. 2005, 5, 421-439.
2. (b) Alanine, A.; Nettekoven, M.; Roberts, E.; Thomas, A. W. Lead generation-enhancing the success of drug discovery by investing in the hit to lead process. Comb. Chem. High Throughput Screening 2003, 6, 51-66.
3. (c) Bleicher, K. H.; Nettekoven, M.; Peters, J.-U.; Wyler, R. Lead generation: sowing the seeds for future success. Chimia 2004, 58, 588-600.
4. (d) Michne, W. F. Hit-to-lead chemistry: A key element in new lead generation. Pharm. News 1996, 3, 19-21.
5. Proudfoot, J. R. Drugs, leads, and drug-likeness: An analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 2002, 12, 1647-1650.
6. (a) Karin, M. How NF-κB is activated: The role of the IκB kinase (IKK) complex. Oncogene 1999, 18, 6867-6874.
7. (b) Karin, M. The beginning of the end: IκB kinase (IKK) and NF-κB activation. J. Biol. Chem. 1999, 274, 27339-27342.
8. (c) Tak, P. P.; Firestein, G. S. NF-κB: A key role in inflammatory diseases. J. Clin. Invest. 2001, 107, 7-11.
9. (d) Karin, M.; Yamamoto, Y.; Wang, Q. M. The IKK NF-κB system: A treasure trove for drug development. Nat. Rev. Drug Discovery 2004, 3, 17-26.
10. (e) Arkan, M. C.; Hevener, A. L.; Greten, F. R.; Maeda, S.; Li, Z.-W.; Long, J. M.; Wynshaw-Boris, A.; Poli, G.; Olefsky, J.; Karin, M. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11, 191-198.
11. (f) Cai, D.; Yuan, M.; Frantz, D.; Melendez, P. A.; Hansen, L.; Lee, J.; Shoelson, S. E. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat. Med. 2005, 11, 183-190.
12. (a) Baeuerle, P. A.; Baltimore, D. NF-κB: Ten years after. Cell 1996, 87, 13-20.
13. (b) Senftleben, U.; Karin, M. Crit. Care Med. 2002, 30, S18-S26.
14. Roshak, A. K.; Callahan, J. F.; Blake, S. M. Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint disease. Curr. Opin. Pharmacol. 2002, 2, 316-321. Abbreviations used in this section: IL (interleukin); TNF (tumor necrosis factor); LPS (lipopolysaccharide); MCP (monocyte/macrophage chemoattractant protein); RANTES (regulated on activation, normal T-cell expressed and secreted); ICAM (intercellular adhesion molecule); VCAM (vascular cell adhesion molecule); COX (cyclooxygenase); iNOS (inducible nitric oxide synthase); MMP (matrix metalloproteinase).
15. Karin, M.; Delhase, M. The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signaling. Semin. Immunol. 2000, 12, 85-98.
16. Delhause, M.; Hayakawa, M.; Chen, Y.; Karin, M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 1999, 284, 309-313.
17. Hu, Y.; Baud, V.; Delhase, M.; Zhang, P.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 1999, 284, 316-320.
18. Li, Q.; Van Antwerp, D.; Mercurio, F.; Lee, K.-F.; Verma, I. M. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 1999, 284, 321-325.
19. For a description of one mechanism of compound promiscuity see: McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem.2002, 45, 1712-1722.
20. (a) Rishton, G. M. Reactive compounds and in vitro false positives in HTS. Drug Discover Today 1997, 2, 382-384.
21. (b) Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today 2003, 8, 86-96. See also 1a for more examples of structural filters.
22. (a) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25.
23. (b) Walters, W. P.; Ajay; Murcko, M. A. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 1999, 3, 384-87.
24. (c) Walters, W. P.; Murcko, M. A. Prediction of 'drug-likeness'. Advanced Drug Delivery Rev. 2002, 54, 255-271.
25. (d) Clark, D. E.; Pickett, S. D. Computational methods for the prediction of 'drug-likeness'. Drug Discovery Today 2000, 5, 49-58.
26. (e) Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev. 2003, 23, 302-321.
27. For a more stringent property assessment describing "lead-like" characteristics see: (f) Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The Design of Leadlike Combinatorial Libraries. Angew. Chem., Int. Ed. 1999, 38, 3743-3748.
28. (g) Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
29. Aminothiophenecarboxamide 2 has been identified and described recently by others as an inhibitor of IKKβ. See: (a) Baxter, A.; Brough, S.; Cooper, A.; Floettmann, E.; Foster, S.; Harding, C.; Kettle, J.; McInally, T.; Martin, C.; Mobbs, M.; Needham, M.; Newham, P.; Paine, S.; St-Gallay, S.; Salter, S.; Unitt, J.; Xue, Y. Hit-to-lead studies: The discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 2817-2822.
30. (b) Kishore, N.; Sommers, C.; Mathialagan, S.; Guzova, J.; Yao, M.; Hauser, S.; Huynh, K.; Bonar, S.; Mielke, C.; Albee, L.; Weier, R.; Graneto, M.; Hanau, C.; Perry, T.; Tripp, C. S. A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin- 1β-stimulated synovial fibroblasts. J. Biol. Chem. 2003, 278, 32861-32871.
31. Other series of IKKβ inhibitors have recently been described. See (c) Bingham, A. H.; Davenport, R. J.; Gowers, L.; Knight, R. L.; Lowe, C.; Owen, D. A.; Parry, D. M.; Pitt, W. R. A novel series of potent and selective IKK2 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 409-412.
32. (d) Murata, T.; Shimada, M.; Sakakibara, S.; Yoshino, T.; Kadono, H.; Masuda, T.; Shimazaki, M.; Shintani, T.; Fuchikami, K.; Sakai, K.; Inbe, H.; Takeshita, K.; Toshior, M.; Umeda, M.; Bacon, K. B.; Ziegelbauer, K. B.; Lowinger, T. B. Discovery of novel and selective IKK-β serine-threonine protein kinase inhibitors. Part 1. Bioorg. Med. Chem. Lett. 2003, 13, 913-918.
33. (e) Murata, T.; Shimada, M.; Kadono, H.; Sakadibara, S.; Yoshino, T.; Masuda, T.; Shimazaki, M.; Shintani, T.; Fuchikami, K.; Bacon, K. B.; Ziegelbauer, K. B.; Lowinger, T. B. Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 2: Improvement of in vitro activity. Bioorg. Med. Chem. Lett. 2004, 14, 4013-4017.
34. (f) Murata, T.; Shimada, M.; Sakakibara, S.; Yoshino, T.; Masuda, T.; Shintani, T.; Sato, H.; Koriyama, Y.; Fukushima, K.; Nunami, N.; Yamauchi, M.; Fuchikami, K.; Komura, H.; Watanabe, A.; Ziegelbauer, K. B.; Bacon, K. B.; Lowinger, T. B. Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 3: Orally active antiinflammatory agents. Bioorg. Med. Chem. Lett. 2004, 14, 4019-4022.
35. (g) Bonafoux, D.; Bonar, S.; Christine, L.; Clare, M.; Donnelly, A.; Guzova, J.; Kishore, N.; Lennon, P.; Libby, A.; Mathialagan, S.; McGhee, W.; Rouw, S.; Sommers, C.; Tollefson, M.; Tripp, C.; Weier, R.; Wolfson, S.; Min, Y. Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3- thiophenecarboxamides. Bioorg. Med. Chem. Lett. 2005, 15, 2870-2875.
36. Catalyst, version 4.0; Accelrys Inc.: San Diego, CA.
37. For recent references to structural information for kinase inhibitors see Cherry, M.; Williams, D. H. Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights. Curr. Med. Chem. 2004, 11, 663-673.
38. (b) Buijsman, R. Structural aspects of kinases and their inhibitors. In Chemogenomics in Drug Discover); Kubinyi, H., Muller, G., Eds.; Wiley-VCH: New York, 2004; Vol. 22, pp 191-217.
39. Freeman, F.; Kim, D. S. H. L. Preparation of 2-alkyl- and 2-aryl-5-amino-4-cyano-1,3-oxazoles. Tetrahedron Lett. 1989, 2631-2632.
40. Youssefyeh, R. D.; Brown, R. E.; Wilson, J.; Shah, U.; Jones, H.; Loev, B.; Khandwala, A.; Leibowitz, M. J.; Sonnino-Goldman, P. Pyrido[3′, 2′:4,5]thieno[3,2-d]-N-triazines: A new series of orally active antiallergic agents. J. Med. Chem. 1984, 27, 1639-1643.
41. (a) Cirillo, P.; Cywin, C. L.; DiSalvo, D.; Ginn, J.; Emeigh, J.; Fleck, R. W.; Hao, M.-H.; Mickey, E.; Liu, W.; Marshall, D. R.; Morwick, T.; Nemoto, P.; Sorcek, R.; Sun, S.; Wu, J.-P.; Young, E. Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses. U.S. Patent US6974870, 2005.
42. (b) Chen, Z.; Cywin, C. L.; Emeigh, J.; Fleck, R. W.; Hao, M.-H.; Mickey, E.; Liu, W.; Marshall, D. R.; Morwick, T.; Nemoto, P.; Sorcek, R.; Sun, S.; Wu, J.-P. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses. U.S. Patent US6964956, 2005.
43. Lin, J.; Sahakian, D. C.; de Morais, S. M. F.; Xu, J. J.; Polzer, R. J.; Winter, S. M. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem. 2003, 3, 1125-1154.
44. (a) Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
45. (b) Lawrence, D.; Niu, J. Protein kinase inhibitors: The tyrosine-specific protein kinases. Pharmacol. Ther. 1998, 77, 81-114.
46. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
47. Yazdanian, M.; Glynn S. L.; Wright, J. L.; Hawi, A. Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res. 1998, 15, 1490-1494.
48. Microsomal stability data generated at Cerep, Inc.
49. Crespi, C. L., Stresser, D. M. Fluorometric screening for metabolism-based drug-drug interactions. J. Pharmacol. Toxicol. Methods 2000, 44, 325-331.
50. (a) Biosource, DAL1100 was used according to the manufacturer's instructions to assess cell toxicity in HeLa.
51. (b) O'Brien, J.; Wilson, I.; Orton, T.; Pognan, F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 2000, 267, 5421-5426.
52. (c) Nociari, M. M.; Shalev, A.; Benias, P.; Russo, C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J. Immunol. Methods 1998, 213, 157-67.
53. Wu, J.-P. et al., to be submitted for publication.